As is generally the case for many areas of the stock market, summer marks a pronounced slowdown in newsflow and stock action for the healthcare sector. Although these periods can be frustrating for investors and traders who crave action, the sluggish pace of trading can afford others an opportunity to get caught up on due diligence and begin establishing positions.

Investopedia Broker Guides: Enhance your trading with the tools from today's top online brokers.

Two Significant Cancer Companies Heading in Opposite Directions
With little of note on the horizon on this weekend, a quick look back at last week seems in order as it was a notable week for at least two oncology-focused biotechnology companies.

Dendreon (Nasdaq:DNDN) reported yet another disappointing quarter; a quarter that saw not only a significant restructuring announcement, but also a sequential decline in sales of the controversial cancer vacine Provenge. Although lauded as a first-of-its-kind therapy, Provenge has simply not caught on with the oncology community - likely due to a combination of its unconventional nature and the lack of response seen in traditional indicators (Provenge doesn't appreciably shrink tumors or lower PSA levels). While management believes that its latest round of cuts will allow the company to break even at $100 million in quarterly sales, very competitive new drugs from Johnson & Johnson (NYSE:JNJ) and Medivation (Nasdaq:MDVN) may make even that level of revenue production difficult.

SEE: How To Choose A Healthcare Plan

Speaking of Medivation, the company announced last weak that the FDA has set a PDUFA date for its heralded prostate cancer drug enzalutamide. On or about November 22, investors will know whether the FDA has approved the drug for sale in the United States or whether Medivation (and partner Astellas) will have to submit additional data.

The K-V Story Ends with a Whimper
This past weekend also saw the likely end of former controversial specialty drug company K-V Pharmaceutical, as the company declared Chapter 11 bankruptcy.

SEE: An Overview Of Corporate Bankruptcy

K-V had largely bet the company's future on Makena - a drug designed to prevent premature births. The controversy came from the fact that K-V had conducted trials and sought approval for Makena as an orphan drug, but compounding pharmacies had been producing the treatment (legally) for patients for years. Whereas pharmacies were charging $300 or less for a course of treatment, K-V initially tried to price Makena at around $25,000 without offering any appreciable improvement in safety or efficacy (rather, just the consistency of a single manufactured product versus the potential variability from compounding pharmacies).

K-V tried to enlist the FDA to eliminate the cheaper competition and force compounding pharmacies to cease selling their cheaper generic alternative as part of the orphan drug designation, but widespread public outrage (including the involvement of Congress) and an unclear legal precedent ultimately led the FDA to back down. K-V tried to reprice the drug (cutting the price by more than half), but could not gain any headway.

SEE: 5 Things To Know About Managing Your Healthcare Deductible

The Bottom Line
The performance of healthcare stocks (as measured by ETFs) has begun to falter a bit. The Health Care Select Sector SPDR (ARCA:XLV) is up around 9.3% year-to-date, slipping below the the 9.7% return of the S&P 500. The iShares Dow Jones US Pharmaceuticals ETF (ARCA:IHE) is up 12.6%, while the iShares Dow Jones US Medical Devices ETF (ARCA:IHI) is up 8.1%. The SPDR S&P Biotech ETF (ARCA:XBI) has risen more than 30% year-to-date.

At the time of writing, Stephen D. Simpson did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Economics

    India: Why it Might Pay to Be Bullish Right Now

    Many investors are bullish on India for all the right reasons. Does it present an investing opportunity?
  2. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  3. Investing Basics

    Building My Portfolio with BlackRock ETFs and Mutual Funds (ITOT, IXUS)

    Find out how to construct the ideal investment portfolio utilizing BlackRock's tools, resources and its popular low-cost exchange-traded funds (ETFs).
  4. Investing

    What Investors Need to Know About Returns in 2016

    Last year wasn’t a great one for investors seeking solid returns, so here are three things we believe all investors need to know about returns in 2016.
  5. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  6. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  7. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  8. Investing

    3 Things About International Investing and Currency

    As world monetary policy continues to diverge rocking bottom on interest rates while the Fed raises them, expect currencies to continue their bumpy ride.
  9. Stock Analysis

    The Top 5 Micro Cap Biotechnology Stocks for 2016 (BSTC, OSIR)

    Discover some of the most promising micro-cap biotechnology stocks that investors can consider for their 2016 investment portfolio.
  10. Investing News

    Chipotle Served with Criminal Probe

    Chipotle's beat muted expectations and got a clear bill from the CDC, but it now appears that an investigation into its E.coli breakout has expanded.
RELATED FAQS
  1. Should mutual funds be subject to more regulation?

    Mutual funds, when compared to other types of pooled investments such as hedge funds, have very strict regulations. In fact, ... Read Full Answer >>
  2. Do ETFs pay capital gains?

    Exchange-traded funds (ETFs) can generate capital gains that are transferred to shareholders, typically once a year, triggering ... Read Full Answer >>
  3. How do real estate hedge funds work?

    A hedge fund is a type of investment vehicle and business structure that aggregates capital from multiple investors and invests ... Read Full Answer >>
  4. Are Vanguard ETFs commission-free?

    While some Vanguard exchange-traded funds (ETFs) are available commission-free from third-party brokers, a large portion ... Read Full Answer >>
  5. Do Vanguard ETFs require a minimum investment?

    Vanguard completely waives any U.S. dollar minimum amounts to buy its exchange-traded funds (ETFs), and the minimum ETF investment ... Read Full Answer >>
  6. Can mutual fund expense ratios be negative?

    Mutual fund expense ratios cannot be negative. An expense ratio is the sum total of all fees charged by an asset management ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center